我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

缬沙坦治疗不稳定型心绞痛的疗效和安全性(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第4期
页码:
502
栏目:
临床研究
出版日期:
2011-08-25

文章信息/Info

Title:
Clinical observation of valsartan in patients with unstable angina pectoris
作者:
杨海娜1; 王伟2; 卢绍禹3; 端木伟文3
1.天津医科大学研究生院,天津300070；2.天津胸科医院心内六科,天津300051；3.天津市第四医院内科，天津300222
Author(s):
YANG Hai-na1;  WANG Wei2;  LU Shao-yu3;  DUAN MU Wei-wen3
1.Graduate School, Tianjin Medical University, Tianjin 300070, China; 2.Sixth Department of Cardiology, Tianjin Chest Hospital, Tianjin 300051, China; 3.Department of internal medicine, Fourth People’s Hospital of Tianjin City, Tianjin 300222, China
关键词:
缬沙坦; 心绞痛; 不稳定型; 高血压; 原发性; 心肌缺血; ST段改变
Keywords:
valsartan;  unstable angina pectoris;  hypertention;  myocardial ischemia;  ST segment changes
分类号:
R541.4
DOI:
61-1268/R.20110503.1634.021
文献标识码:
A
摘要:
目的:观察缬沙坦治疗不稳定型心绞痛（Unstable angina pectoris,UAP）的疗效及安全性。方法： 选择UAP患者120例，随机分为常规组（60例）和缬沙坦组（60例）。常规组：常规治疗，包括硝酸酯类药物、阿司匹林、β-受体阻滞剂及他汀类药物，连续服药6个月，缬沙坦组在常规治疗的基础上加缬沙坦80～160 mg，每天1次。观察治疗前后患者心绞痛临床症状的改善情况、心绞痛发作次数的改变、心电图ST段变化、血压变化及左心室肥厚的改变等情况。结果： 治疗后，常规组和缬沙坦组心绞痛临床症状明显缓解，发作次数减少，ST-T段压低减轻，左心室肥厚明显逆转（均P<0.05），缬沙坦组改善更显著（P<0.05），两组患者的血压均明显下降（P<0.05），但两组比较差异无统计学意义。结论： 在UAP常规治疗的基础上，加用缬沙坦，对UAP治疗的疗效、安全性及耐受性均好。
Abstract:
AIM:To observe the curative effect and safety of valsarton on unstable angina pectoris (UAP). METHODS: One hundred and twenty UAP patients were randomly divided into two groups: normal control group and valsartan group. For 6 months, patients in normal control group were given conventional treatment (nitrate acid ester, aspirin, β-receptor blocker and statins) and patients in valsartan group were given conventional treatment plus valsartan (40-80 mg/qd). Changes in clinical symptoms of angina, anginal attack frequency, electrocardiogram of ST-T segment, blood pressure and left ventricular hypertrophy were observed. RESULTS: Clinical symptoms of angina in the two groups were assuaged, attack frequency decreased, ST depression was reduced and left ventricular hypertrophy was reversed (P<0.05). Blood pressure of the two groups decreased (P<0.05) but with no significant difference between groups. CONCLUSION: On the basis of conventional therapy, valsartan has a reliable curative effect, good safety, more tolerance and few side effects in treatment of patients with UAP.

参考文献/References

[1]中华医学会心血管病分会，中华心血管病杂志编辑委员会. 中国不稳定型心绞痛和非ST段抬高心肌梗死诊断与治疗指南［J］ . 中华心血管病杂志，2007, 35(4):295-304.
[2]朱丹，高炜. 炎症因子在急性冠脉综合征中的意义［J］. 国际心血管病杂志, 2009, 36(5)：257-259.
[3]张慧敏，孙丽颖，张密林. 急性冠脉综合征与内皮功能障碍［J］. 临床荟萃， 2006, (3)：210-211.
[4]Koenig W, Khuseyinove N. Biomarkers of atherosclerotic plaque instability and rupture ［J］. Arterioscler Thromb Vasc Biol, 2007, 27(1):15-26.
[5]桑圣刚，荣红. 急性心肌梗死患者血管内皮细胞损伤的电镜观察［J］.中国急救医学， 2009, 29(8)：738-740.
[6]Fleming I, Kohlstedt K, Busse R. The tissue renin-angiotensin system and intracellular signaling ［J］. Curr Opin Nephrol Hypertens, 2006, 15(1):8-13.
[7]翟振艳,向光大. 血管紧张素受体拮抗剂对高血压患者血管内皮的影响［J］. 临床内科杂志， 2010， 27（1）：70-71.
[8]Locatelli F, Del Vecchio L, Caballi A. Inhibition of the Renin-Angiotensin System in Chronic Kedney Disease: A Critical Look to Single and Dual Blockade［J］. Nephron Clin Pract, 2009, 113(4):286-293.
[9]Ikeda N, Nishimura S, Kyo S, et al. Valsartan cardio-renal protection in patients undergoing coronary angiography complicated with chronic renal insufficiency(VAL-CARP) trial: rationale and design［J］. Circ J, 2006, 70(5):548.
[10]李晓东，贾晨红，杨志勇，等. 依贝沙坦、缬沙坦和氯沙坦对高血压左室肥厚的影响［J］. 中国误诊学杂志， 2007， 7(1)：3-5.
[11]陈刚，江志忠. 缬沙坦对原发性高血压患者左室肥厚的影响［J］. 广东医学， 2007， 28（12）：2018-2019.
[12]Schfer A, Fraccarollo D, Tas P, et al. Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism［J］. Eur J Heart Fail, 2004, 6(2):151-159.
[13]Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study［J］. Cardiovasc Ther, 2009, 27(3):151-158.
[14]Bahlmann FH, de Groot K, Mueller O, et al. Stimulation of endothelial progenitor cells: a new putative therapeutie effect of angiotensin II receptor antagonists［J］. Hypertension, 2005, 45(4):526-529.
[15]Black HR, Bailey J, Zappe D, et al. Valsartan: More Than a Decade of Experience［J］. Drugs, 2009, 69(17):2393-2414.

备注/Memo

备注/Memo:
收稿日期：2010-11-23.通讯作者：王伟，主任医师，主要从事冠心病基础与临床及介入治疗研究 Email：greatwhlm@yahoo.com 作者简介：杨海娜，主治医师，硕士生Email：doctorhaina@sina.com
更新日期/Last Update: 2011-06-02